Literature DB >> 21505840

[Diabetic nephropathy].

J Menne1, H Haller.   

Abstract

Diabetic nephropathy is the most common cause of end-stage renal disease. Since the disease progresses very slowly and usually takes more than 20 years before terminal renal failure occurs, early intervention is of great importance in order to prevent this disabling complication. A good control of diabetes with HbA(1c) levels around 7% is desirable. At least as important is the treatment of elevated blood pressure values. The target value for patients with diabetes has been adjusted in the last year and is now 130-139/80-85 mmHg. Should (micro-)albuminuria or renal insufficiency be present the blood pressure target is <130/80 mmHg. For the control of hypertension the use of ACE inhibitors or angiotensin receptor blockers is recommended. In addition, the control of other risk factors and appropriate therapeutic intervention is required. A multifactorial intervention leads to the best results and can avoid the occurrence or progression of diabetic kidney disease and other micro- and/or macrovascular complications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21505840     DOI: 10.1007/s00108-010-2761-8

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  21 in total

1.  Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts.

Authors:  Ron T Gansevoort; Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh
Journal:  Kidney Int       Date:  2011-02-02       Impact factor: 10.612

2.  First morning voids are more reliable than spot urine samples to assess microalbuminuria.

Authors:  Elsbeth C Witte; Hiddo J Lambers Heerspink; Dick de Zeeuw; Stephan J L Bakker; Paul E de Jong; Ronald Gansevoort
Journal:  J Am Soc Nephrol       Date:  2008-12-17       Impact factor: 10.121

3.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

Review 4.  Structural involvement in type 1 and type 2 diabetic nephropathy.

Authors:  M Dalla Vestra; A Saller; E Bortoloso; M Mauer; P Fioretto
Journal:  Diabetes Metab       Date:  2000-07       Impact factor: 6.041

Review 5.  From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines.

Authors:  Bieke F Schrijvers; An S De Vriese; Allan Flyvbjerg
Journal:  Endocr Rev       Date:  2004-12       Impact factor: 19.871

6.  Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.

Authors:  Folkert W Asselbergs; Gilles F H Diercks; Hans L Hillege; Ad J van Boven; Wilbert M T Janssen; Adriaan A Voors; Dick de Zeeuw; Paul E de Jong; Dirk J van Veldhuisen; Wiek H van Gilst
Journal:  Circulation       Date:  2004-10-18       Impact factor: 29.690

7.  Relation between kidney function, proteinuria, and adverse outcomes.

Authors:  Brenda R Hemmelgarn; Braden J Manns; Anita Lloyd; Matthew T James; Scott Klarenbach; Robert R Quinn; Natasha Wiebe; Marcello Tonelli
Journal:  JAMA       Date:  2010-02-03       Impact factor: 56.272

8.  Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.

Authors:  Naoyuki Nakao; Ashio Yoshimura; Hiroyuki Morita; Masyuki Takada; Tsuguo Kayano; Terukuni Ideura
Journal:  Lancet       Date:  2003-01-11       Impact factor: 79.321

9.  Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality.

Authors:  Hiddo J Lambers Heerspink; Auke H Brantsma; Dick de Zeeuw; Stephan J L Bakker; Paul E de Jong; Ron T Gansevoort
Journal:  Am J Epidemiol       Date:  2008-09-05       Impact factor: 4.897

10.  Effect of a multifactorial intervention on mortality in type 2 diabetes.

Authors:  Peter Gaede; Henrik Lund-Andersen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245

View more
  1 in total

1.  Diagnostic value of the combined measurement of serum hcy, serum cys C, and urinary microalbumin in type 2 diabetes mellitus with early complicating diabetic nephropathy.

Authors:  Tengkai Wang; Qian Wang; Zhimei Wang; Zuomin Xiao; Lunqin Liu
Journal:  ISRN Endocrinol       Date:  2013-09-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.